XTL BiopharmaceuticalsXTLB
13F holders, Q4 2025 (December 31)6holders +2
3new positions
1sold out
1famous investor
$0.58avg. 13F price*
At the end of Q4 2025, 6 institutions reported holding XTL Biopharmaceuticals Ltd. (XTLB) in their 13F filings, up 2 from Q3 2025. 3 opened new positions and 1 sold out. The largest holders were Noked Israel Ltd ($115K), Citadel Advisors ($44K) and Rhumbline Advisers ($17K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- XTL Biopharmaceuticals Ltd.
- CUSIP
- 98386D307
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $57K |
| Exits | 1 | $893 |
All 13F filers, Q3 2025 → Q4 2025: 111,838 shares bought and 9,034 shares sold, net +102,804 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Noked Israel Ltd | 0.02% | No change | 198,888 | $115K |
| Citadel Advisors | 0.00% | New | 75,866 | $44K |
| Rhumbline Advisers | 0.00% | Add +74.4% | 30,108 | $17K |
| GAMMA Investing LLC | 0.00% | New | 12,887 | $7K |
| XTX Topco Ltd | 0.00% | New | 10,238 | $6K |
| Morgan Stanley | 0.00% | Reduce -82.6% | 1,740 | $1K |
"% of holder's portfolio" is XTLB's weight in each manager's 13F, not the share of XTL Biopharmaceuticals Ltd. the manager owns.